Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPM2NZOE9ZTDVqcC1RQ1lVVHZPRThhVEpOeVAxQUFSLXJlX25qZWQzWmp3YWJuaGxCdVNQalhtdTllSnNycVFzNkdLNFh4SFdJbFpFRmtSMC1jSjJIdk5TeEROZzdyZHJiQ3MzN1ZFd2NBLVVaUUdYZ2JDeWRtaUdaWFhkRWlRMWJRWm5kekgyY09MemQyRUhUZVJHOExuMkVIbkZOSDZRR3RZbzQ?oc=5" target="_blank">Extended Risk-Adapted Therapy Improves Survival in High-Risk Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
Bears DE Montez Sweat suspended 2 days for drug violation
Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film
Bengals tight end Tanner Hudson out for season with torn pec
The top reason to watch every NHL team in the Frozen Frenzy
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQVVIwUXROLU1KYnhVTzd3Q2Rwa1hnSEQtMHJKTWZONjFfRi1LRGdrdW1fUTJ4aGNyaU9KUUpJTXN1SGFoSWxNWjBJdk9KYU9mNmVqeFl2UzJfbHhDRUQ0Z1ktdEJ0S0cybzJVLUNBUmlCdlJzNUk4S3NkcnZkcjBpOTVEN0s?oc=5" target="_blank">Iberdomide Triplet Improves PFS by 51% in Phase 3 Myeloma Trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQXzd3YnBUSFpmbkZ0ZXBFdWZSdjRlUUtFclJkNG1zRHFuOXhzX1VLSGtNOWtoOWFWS0tOT2dnX3pVVm5RUU0yRUVkYzd0NnV1djRNSkYwNm4tVS1XTGxvNGNBUjJyUUdEZjNyWDQzdmpwSU1PQ09CbHp5c0lVWWNxV2F5VGx1SElsS1JUV3lmRQ?oc=5" target="_blank">Teclistamab Improves Outcomes in Relapsed Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">University of Miami</font>
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOR190YU1ycEJqSHZNSmtDVllNMFhwUlpZU3F0UEJuVldwb0pLbHBDbUtaSDdGNHRrcGwtQU9OTkw1WXVsalZGdkR0eXU0a3c4ekE5dlFfQkw5YVJzMm5VQ1ZqbkRfdXRseDgxTjdmOE01V0RXR1NLZ216VjVlajFZSDhkbG1tRzJKUk85ZklnZzZEMDlHUTZlTzVqRUNoVVdDaVFfZ1N3?oc=5" target="_blank">Iberdomide Triplet Improves MRD-Negative CRs in R/R Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPQ2JvS0duQUd5eW1lWGIyay1JZ2JocVY4OWQ3bFFubnNOT0V3Tk9TVTZlRUdrd3JvYThiWHk0UXJFWWRMLVdkM1JMUEdNNnBXMFN2LTVFV3JkdUdHNnBnbk5oRnhVcFpLVW5XdTA4eUE2ZF96NHZER1IySjA5MDgxb3R4NGFCVE1OdmVJVXltTEZObVlZN0tza1BFU1h6dTJEbERHSFlCZEZOQV9POG5HV19FQTBNWW9tdXdQVWpmRXRTWS1aVVFERURqWndRWG9qRHp6N0g4dVRxMWRCR2xLZHhiTVhsVGc3MjVVZ2RHNA?oc=5" target="_blank">Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy</a>&nbsp;&nbsp;<font color="#6f6f6f">Mayo Clinic News Network</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPcHRZdnR1MzVwOUdGSEQ3akFxSTY0VTdJRlJSVkNiQkh4M25OU3lhOWhPbEFwbld3Q0toLTV6WW9sWVNTWWEzQ3VsdTBBRUJueWFqTTVUZWxHVVl3MFoxUWlEdUw0SE9XXy0teGJPUGVaeS13eGxTTU83UGhtQ3o2ejlBelFqQU9ocVFteWJVeGtLWGg2bUstWERoeWgyV2JrU0lSNWhjbkR4N0NIMWc?oc=5" target="_blank">Talquetamab-Based Combinations Improve Outcomes for Relapsed Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">https://news.cancerconnect.com/</font>
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMkpRZGdfejRsYUNBXzE0a2VYdlZuaDBBN2l1NHZxODF4U3ZwWWZ0RFhXNHlUVUpoVFh5QTV4TWdpM25IOXB0Sk43TUJXX1JOVHJuVGtOY2Vram1aX01MbHJsazVvTFplVXhCUExVRWh4QWxNcmlZLWpFWDZ6YnRnRVp3cVJSUUw2Rk5IYkxfVWVkd1VIeWZrRjVPWW5TbEFFU0JQMG0zSm5NOGtPUjNOejYzeDZlSmhwbkVleWZFbzNnQkd6dkZZdElwTFpRbm5VUVE?oc=5" target="_blank">Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNczFRelJ4bWxYVnlMTTJRYzZwcm1BeVhzdkRBeWlZUlFEc1JJdmw0TENOZWpaT0JWMjZudlVNQ3RSMU9nV1pweXJfTkRXU1FkemN5a0N6ajViVnRQeUlQbFhYNEVEcVF3bDVkUkNCUEZPTFdiblhlVFRDWExGR0N4NWlheFV2ZlIyTVB5ZVVVbE90QmhGcy12a3BocDJpVE5uWWRQY2ZFUDdhcGF1QWRobTVzeFh3WGtRQ1ZXcTc4ckVkSXJmaFZBTHZiU1h3QQ?oc=5" target="_blank">Artificial intelligence-based tool could improve multiple myeloma treatment decisions</a>&nbsp;&nbsp;<font color="#6f6f6f">News-Medical</font>
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPLXc5dWw0ZG5fTlF2dUVkYi0tdWUtc0cxXzlEbUgyckdETkRJWW5nTEY5Wlh5QS1CRkNoM3Q5cjgzRklvRHNfa2hIajVXUkxnVmdpd0xFdUZtbThKYmZJdm5WWk03M0NQSXBHZWVFRkdSWTJvZlBKZDFmdHM4T1ZiM2dUU2xBZm5sZUVN?oc=5" target="_blank">Combo treatment delays multiple myeloma progression and may improve survival, study finds</a>&nbsp;&nbsp;<font color="#6f6f6f">Medical Xpress</font>
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPZVBFM1lrRFl0dGR6d2Y4bFdMQW5NMEdLOF9Jc2RWMFZtelp6cjdhclBFUWZVUHVwcUZrU0s5R2xsVG9od0ZpOXV0WnFPZTVPclJTMS03WFFMdDRobV9vZGFBUV9Gb0cxdGc2djBWbTNBekFSdG90Mk9PN2hWWTNxZGdnTnM2UE1Qc0VEOUpYRElsa21sRU9ocFN3WkdqZzd3UExKUEJVM19YMGNRRTNPLWhmeDRveElTMWc?oc=5" target="_blank">Etentamig Improves Responses and Progression-Free Survival in Relapsed Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxONHhHSWhUbjdmelUzM2xhbWJMQW1oUXVsZmpNalItWUdvdUpSUXlja3Vuc3dDVnAzNDVmM2dwZlRTQXdMR04yLVM0eWxHN0k2ZF8tX2N6SE5Xc2dNWk1GUmszaEdrRTZCNlBiQUNsYWZ6NEJmVEJtMkRtMGNyQ3p5VUQ2Q0dIYUlUNUdkZlZNeGdoLXhzVVNUTmhfUmJuMWx0czZEVk5MQ3NVb2F5QzU4?oc=5" target="_blank">Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNZWZwcGk4dDBoV2NpN2Z4b05NRHNXbHdUbFl1UnByS2VWLXo4UUw2NV9ONHB1QVNQT3FrNS15SjBSQjJRYjZuRnNvdXprSzMwREtwdzBacTV3Tnp2S3RPemwxUGRDMWhNeVlUNVpuWVJoVnJPeGJRY3dhYkdfTTVQSTYxcFBtVnhCQURMMjBtNDNBODV4Vlp6NVFsOWl1YTVma1VhUng3RTRha08xNmc4aVJkWGRxRmxpQkE?oc=5" target="_blank">Talquetamab-Based Regimens Improve Survival in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Cancer Therapy Advisor</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYlBoSHllQTFSb18wVW5meHB0ZnJhbEd6WkJjSnlkY1FleFpRMG5rOElueW5VZjFuSzBiR2FFeDMxSTcyb3J2b1gwTkZVOW1mRWlXSkZWWElkS3BLYXNZeUd5MzlLNlJMaVdnTUtzcm5XLU5nTjY0c0RpdHhMeXoxWVFaaEJPcllQQzNGcXR3cjFZSTU4aVRUdi16cWg0Y1d3MlRnaEtqN1JsQ1Q4SWdtT2ZleDlpN3E2bkF6Rg?oc=5" target="_blank">Addressing CAR-T Therapy Challenges in Extramedullary Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Hematology Advisor</font>
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOZVh2VUNSY09VMHYyUzRodnowVjE2VF9nVVFOeHF5MG5meXdpdkU0bnZEUEo1TFAyekZtMlY5ME1ieWNIeWlkcWRPeWNGUXprQXl3clctb2JkN2tjUWVaMnFBQ0V5NUpkYmZBRndBbC1uZ3g1QW9OX29wb3dSZnE2NktfSnN5VzUxZGZyRlRsNzJ1TFpxaDU0YzRPTDdXcWxBY2cxaWhR?oc=5" target="_blank">Improving how multiple myeloma is understood and treated</a>&nbsp;&nbsp;<font color="#6f6f6f">Mayo Clinic News Network</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQMmw5ZF9JeTRVVF9kcHp1Sy0zMlVJaHhBdzZYbXVUU2RPV1ZDNEZIT01DTE95N19WSFJhYkNUVVo5eEtmdkRIc19SZ1BpR2Q0S014UUhFVnlQUFZnMksxenhfOUt5NHcwNlZabklKX3owVW0tRnBfMGpGR0NxTmMyUF90WGV6ems5TVkxTnBhMENOMXhORkF4NUFtVzFOVTZsUjh3RGNZaGNYaWdY?oc=5" target="_blank">Teclistamab Combos Improve PFS, OS in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPekpFdzkxdHVadERDcFVETlJNWUhiUkw2QzduYXY3TVh2RUx5U1h2QjA4X0pNVnhNZnVBWTNLOFNJVFVnZG42SnJyWmVpc3VJeTVVMjZPMU5JYmt4OWFiWnlQRlRRR2E2MlNUdXZkb3hsQ1k1X2ZRbE81bUFxSjJkVm8xYXNvSXNPeGgzbXZlTFpkdnJNcVY5SURfcUxvaUhrZlFpTHVZWFRKaTRz?oc=5" target="_blank">Elrexfio Improves Progression-Free Survival in Multiple Myeloma Phase 3 Trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPVi1zMElXYTN0SUpQMng2TDQxa3hDRVlVM1IzOUlGUlFFTEltNHgtQUJZbC1yLXIwdk1DRVVfeTR1ZWExelRUUy1PazJVdXN4cGRfNTc5LTgxN2Y0NEFFbVVUQWZyWkQyckhzQ1pleUVBdFNzLVZkcUtKSExKQ013b1ZOM2I2U3Q2aXFSWnVCdmI0dEtFZS1pZXlWdHZMOXNiTXVveUlqYl83emVYMEE?oc=5" target="_blank">Combination Treatment May Improve Multiple Myeloma Outcomes</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPZTdDYTdDNUpRbE9wZ1pwbGwxT1lhNDdBQXpQOWJsUzhSM25paGVmNzQ0LWpoQmZMbWVpWFVzcWo0VFo5dVpSNlZpRDVWLVFwcGt6eTBfMFFVdGxqdHRHZmFyTzBldGM0b183QTEwLW14LWVmc1hSMEo3ZjVfVzlMWFNQV0sxR2RuZXUtb1A1ai1fbHRQdTdXeGhkcXhWQjVOeVRTcmpBbGpfV2VsSmE3UEZDUGJiT21RTW5nUG1qOE4wdWkxeWJHMlpHeXA?oc=5" target="_blank">Teclistamab (Tecvayli) Improves Survival in Relapsed Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOVHVGV3B2TjlqRkxrckRtT3ptc2VYaHhCa1Q5d3ZyaWo3OENESjBsNVE4Njd5eVg5UlNFamtZeEo5amtRSDdMTi12V2pvS3pnWGFob1M3TUZBUTZqcy1rNWhLQ3FEQ05BbGY5T25iaE5wQlYyT1lVbHZGZmJJdDFjZWdxU3REVTZfbXVkTkxxdHQyRi1WQWZ2NE5sSjBQaHBUTGVLazhERmRySzA?oc=5" target="_blank">OS Does Not Improve With Continuous vs Fixed Lenalidomide Dosing in NDMM</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNaFpZMEZMNm56VlFIOUo2MDZtZzdPdkRaS2pHQ25abGtUUWZ2MVEtekY4ZC10dTE0cnF5ZWlXajhzS040QUVKNDR1VkctdHNMMUk5SnBHMGtQV0F0SmdGUUs5S3ZIcXpUYnE1Y1VxbjYtbDFTTjRGTmhTTnUzTWs1TjBoYTdNcHpZTE9PNmVSVWxubDlhcUpLLU1LN1kxSWNHdWp3?oc=5" target="_blank">Etentamig Improves ORR/PFS in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPQkhfSTU0WmVMLWwxRFVSbDZVSW45RVpLYXdzWURoc3djZW1GNVRJQkpDRld0c3dmdThxUG0tbkNCTGsxSEZuT2txUU9uYkszV0VIRmcwM245Ny1GbXoyQXB1NVJFZ2dtV0c3N3VTU2ZORDNaaWp5T0lfNVgzZUpWSG45QmFWQW9kcFFNT2l0bmFVeVdYQ2VqWHpCUGM0OXVqaTBFSlhUNFRWWFEy?oc=5" target="_blank">Multiple Myeloma Death Rates Decline as Targeted Therapies Transform Survival</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQZ19ITTRiUGMzb056cnNOQlZrbERSeEk5RjV6TUVMd2tTT1hSYm9CYmttd3pDTDJVZEtpYnM5N0VqRUE2T0V5aGJaeDZObzJmV0ZRcmJ2ZExhd3NYcC1tNVJNcUlUY210bUYwcy10d2JSajQyUmU2ZXZ5OUdBM0tDVlpqU09xZlpwbFlWLXJWVjB4MVRPUWtLbkNfZ1hHT1lzYnVRSmRobFJfWjFma1UwNUR6Nkd5Xy1JVzM2RjV4eWxXVUtHc3hBeUVCVUFEQQ?oc=5" target="_blank">Iberdomide Plus Daratumumab/Dexamethasone Improves MRD-Negative CR vs DVd in Relapsed/Refractory Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPZEZmS2JEZmtEa0RveEpIUTJsVVNaSWNPVkVNWXVaM3lvRF90N3ZVWkZna2dISFp0dTNyMkJDbWlwYlVvRXQ3ZnVJRUdiV0o1dHJNZUtxUURiMGN6eHFGMnc1b3Q5aFJYQzk3MDZVaVNudEUxR21QQlFBVzFKWUVVYy1kdUhWMlc3aHJfQWg5RFhNbTVXUG1wa3VkUmRPcmVHN2l2ck8wX3d4MWls?oc=5" target="_blank">Linvoseltamab May Improve Outcomes vs Teclistamab in R/R Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQeGsyYnpNSEtXOGdNMU1ud0EzVnpKeDBtd2xpU3dSTDRheFlCRkNDX1Y0R2xOUzRTaDFLMWx5aHZmZ09MYnFOZUZrVHlHOVVCUkNja0RveWhWMGlEczBEUzFZRXd3N29YZzdxT1E4dndSd3FDVnMxOFNaWjlQS2VnQ1k1YzI1WWp6NUU1dVBJQzI4LXpPd0IzaW84U2tWRU0xTmtsVm9TOU1sU3FOVTNvNg?oc=5" target="_blank">The New Era of Multiple Myeloma Care: How Immunotherapy is Redefining What’s Possible</a>&nbsp;&nbsp;<font color="#6f6f6f">AdventHealth</font>
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQTUdGV092Yjd1bDEzZGdCQ1JrZWlQWmJualdjN0FGcHFwLXZISWpDWldVa18xYllILUZNdmlLSDRvNmJjNml3WF82aTNWWDJTclJwbm5wWmhJOGF0X0NydFk3WW9faGFBSFpJeHRDQ2VENTRGUmxBVlNOblFNTGlqU0VTQ0I2U0lRb1YzZGgyZ0dvdTN6b1ExME5sUnBOcWhFY0hKbDlGbFk4YUx5MzlrYV8wSE1HakROcElzRnoyeEdFejFpYVRVSFFnQTJEV283RkNPRmNrOV8?oc=5" target="_blank">Talquetamab-Containing Regimens Significantly Improve PFS in Relapsed/Refractory Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOXVVc1k0dUFpQldEcDB4N3dTLWNjSzlBZEk1SVYxV3JjRTRRX0FfcmRXNTZyb2E5cnhaMWpjaVp6MGxJaWhSbEwxU3g1aVNkM0VEZnV4clBQOXRlbXRfTjVQMjNtZTFYYzZzTVRrcjlIcEktQlJRdDVZcjJJcVNFcmFuc0pHaXI4czdqenFhQ0c1MTFIdDVtallNb19DdXprNEQyNy03Nzk?oc=5" target="_blank">Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFAxeThJLUJJc0dsLUdOVU8yclpXMnAwek5TWWRfajlUUVNUN0VydlFFUmVRc2wtb3A4Umc4ZmZYcF9mMUtvcjdwZlRpYWdfMnNKTUpNWjJuRTVKeV9BN3ZfMnJYckhoWnkzeTNCZWhPYkZkM19OX0tZTFVOUk5MZw?oc=5" target="_blank">Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRWJFdVBFajJyOW1ma3R4bzd3WGFOYXZoYW14bG9uWVpuSE05RG9rSEZDZVRWeTdGeVNfM25lVVRRVkdQWjIzaE11bGdtQmFLVmtjbUNTUlNOdnZrbmQzWWg3N2F3a3pMOW5DRDlhMmtFZGROZ09ZWmZURVBuZXYwTVhlejlPZy1NTjNHMU90QW1Na3VQY2VLb0lSTVhydTl0RC1zc2o4SnEyQQ?oc=5" target="_blank">Trial Challenges Indefinite Maintenance for Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOQjNnS05iVUtuQk4zU2pucERYVzhpVFF2aURMYkdQbkNwZ2k3ZFR5WDZmVUh4NDVzNVBlX0I0ZldzTE9mMFhtRUZPUWtfQVdOSWZBclBuOVNVVDVIVUFvLTFEYm1Ybi16MTVGZi0xSE11Wm1qZUFOY2U3R2xJRDdlRzJEd2swUVd1VlZjeA?oc=5" target="_blank">New advances are transforming blood cancer care</a>&nbsp;&nbsp;<font color="#6f6f6f">Loma Linda University</font>
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQRlZQYlJjZldjaThXTDlpUDRoS0JrdU9JVVk5eDhMTGRBSUk4Nk5QMWhzeTNmMlgyckljRXdON3J3VkNZWEl4NDFyWWdIcmIwZHVhRFQ0c1NVQUtBbDVfMWVXUU1xZER5ZVdMa21YMDFPOEdjOXVJcnp2ZVlBTzlwaGdJc1NCc3hSQmUzR0VvdGF0eDZYY2syUm1JakZBa0ROQkpvcThn?oc=5" target="_blank">Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>